Jennison Associates’s Bio-Rad Laboratories Class A BIO Stock Holding History

Jennison Associates’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-66,234	Closed	-$27.6M	–	581
2022 Q3	$27.6M	Buy	66,234 +1,399	+2%	+$698K	0.03%	271
2022 Q2	$32.1M	Sell	64,835 -3,026	-4%	-$1.58M	0.03%	238
2022 Q1	$38.2M	Buy	67,861 +15,638	+30%	+$9.43M	0.03%	260
2021 Q4	$39.5M	Buy	52,223 +41	+0.1%	+$30.7K	0.03%	262
2021 Q3	$38.9M	Buy	52,182 +22,922	+78%	+$17.2M	0.03%	254
2021 Q2	$18.9M	Buy	29,260 +7,402	+34%	+$4.5M	0.01%	376
2021 Q1	$12.5M	Buy	21,858 +6,975	+47%	+$4.13M	0.01%	403
2020 Q4	$8.68M	Buy	14,883 +5,278	+55%	+$3.01M	0.01%	419
2020 Q3	$4.95M	Buy	9,605 +3,361	+54%	+$1.7M	﹤0.01%	438
2020 Q2	$2.82M	Buy	6,244 +4,329	+226%	+$1.91M	﹤0.01%	453
2020 Q1	$671K	Buy	+1,915	New	+$704K	﹤0.01%	524

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jennison Associates's BIO Position: Q4 2022 in Review

Jennison Associates sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2022, closing a stake of 66,234 shares — an estimated $27.6M sold.

Jennison Associates first reported a position in BIO in Q1 2020 and held it in 11 quarters. The position peaked at $39.5M in Q4 2021. 470 funds tracked by Wall St. Rank hold BIO as of Q4 2022.

Jennison Associates reported no remaining Bio-Rad Laboratories Class A position as of Q4 2022 after selling out during the quarter.
Jennison Associates sold 66,234 Bio-Rad Laboratories Class A shares in Q4 2022, an estimated $27.6M.
Jennison Associates first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 11 quarters.
Jennison Associates's Bio-Rad Laboratories Class A position peaked at $39.5M in Q4 2021.
470 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2022.

Based on Jennison Associates's 13F filing for Q4 2022, filed 9 Feb 2023.